Novartis' Beovu (brolucizumab) Receives FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration
Shots:
- The approval is based on P-III HAWK (NCT02307682) & HARRIER (NCT02434328) studies involves assessing of Beovu (intravitreal injection)- 6mg (HAWK and HARRIER) & 3mg (HAWK) vs Aflibercept (2mg) in 1-800+ patients with wet AMD across 400 centers globally
- The P-III studies demonstrated non-inferiority in mean change BCVA @1yr. (week 48); reductions in central subfield thickness- @1yr. 56% & 51% maintained on the 3mos. dosing interval
- Beovu (RTH258) is the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to 3mos. dosing intervals immediately after loading phase with no compromise in efficacy
Click here to read full press release/ article | Ref: Novartis | Image: Financial times
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com